Toronto, Ontario – Cyclica, an in silico drug discovery company that offers a novel proteome-wide screening predictive analytics platform for the pharmaceutical and related industries, has been recognized by Corporate LiveWire Magazine in their 2016 Healthcare and Life Sciences Award series in the category of “Excellence in Life Saving Therapeutics.” The platform is being used and validated through third-party organizations to develop safer and more effective therapeutics. Whether hypothetical, pre-clinical, clinical, or FDA-approved, Cyclica offers proteome-wide insight and analysis into a small molecule’s effect — augmenting drug discovery pipelines, and efficiently taking assets from bench-to- bedside.
Naheed Kurji, President and CEO of Cyclica, had this to say: “Our customers are looking for a platform that provides a faster and cheaper way to bring safer and more effective medicines to the market. We are therefore seeing a thirst in the drug discovery world for new tools that uncover and validate novel targets, and that help guide strategies efficiently. For the past few years, the Cyclica team has dedicated itself to the development of a novel platform based on an innovative proteome-wide strategy to address critical needs in the industry. With continued customer-centric innovation as a foundational pillar, our aspiration is for Ligand Express™ to be an integral utility platform in the R&D value chain. Being recognized by Corporate LiveWire with this award is an honour, and one that the entire company appreciates and values.”
Cyclica has developed, validated, and patented a structure-based proteome-wide screening platform, Ligand Express™, that currently features PROBEx (proteome-screening), SWITCHx (ligand effect prediction) & DIVEx (systems biology & drug-protein interactomes). Ligand Express™ is unique in that it is a drug-centric platform. For a small molecule ligand, Ligand Express™ automatically generates an intelligent list of ligand-protein interactions by searching through a large proprietary database of all available structurally characterized proteins. The platform provides a panoramic view of a small molecule ligand to better understand on- and off-target interactions, and is valuable in finding novel desirable or undesirable targets. By gaining insights into a ligand’s polypharmacology, Cyclica’s clients can identifyunknown targets, prioritize lead candidates, elucidate adverse effects, and understand repurposing opportunities
About Corporate LiveWire:
Corporate LiveWire is brought to you by Fenice Media Ltd., a publishing house with an international presence. Fenice Media aims to offer a number of platforms for connecting its clients with an exclusive, global audience. The core products offer daily-updated content along with regular magazine publications that can be viewed on all digital platforms.